» Articles » PMID: 29146611

Smooth Muscle-Selective Nuclear Factor-κB Inhibition Reduces Phosphate-Induced Arterial Medial Calcification in Mice With Chronic Kidney Disease

Overview
Date 2017 Nov 18
PMID 29146611
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hyperphosphatemia is a major factor promoting the formation of arterial medial calcification in chronic kidney disease (CKD). However, arterial medial calcification begins to occur during the early stages of CKD, when hyperphosphatemia is not yet apparent. It is predicted that other factors also play a role. The aim of the present study was to determine the role of pro-inflammatory nuclear factor-κB (NF-κB) signaling in smooth muscle cells (SMCs) for phosphate-induced arterial medial calcification in CKD mice.

Methods And Results: We first sought to establish a novel mouse model of CKD with arterial medial calcification. CKD was induced in DBA/2 mice by feeding them a low concentration of adenine, and these mice were fed a normal or high-phosphorus diet. Severe calcification was seen in CKD mice fed the high-phosphorus diet, while it was undetectable in CKD mice fed the normal phosphorus diet or control mice fed the high-phosphorus diet. Arterial medial calcification was accompanied by phenotypic switching of SMCs into osteogenic cells. Interestingly, NF-κB inhibitors, tempol and triptolide, both reduced arterial medial calcification in CKD mice fed the high-phosphorus diet. Moreover, formation of arterial medial calcification, as well as SMC phenotypic switching, was also markedly attenuated in transgenic mice, in which the NF-κB activity was inhibited selectively in SMCs. Mechanistic studies revealed that Krüppel-like factor 4 was involved in NF-κB-induced SMC phenotypic switching and calcification.

Conclusions: Results of the present studies suggest that the NF-κB signaling in SMCs plays an important role in high phosphate-induced arterial medial calcification in CKD.

Citing Articles

Gla Rich Protein (GRP) Mediates Vascular Smooth Muscle Cell (VSMC) Osteogenic Differentiation, Extracellular Vesicle (EV) Calcification Propensity, and Immunomodulatory Properties.

Viegas C, Carreira J, Maia T, Macedo A, Matos A, Neves J Int J Mol Sci. 2024; 25(22).

PMID: 39596469 PMC: 11594964. DOI: 10.3390/ijms252212406.


Chronic kidney diseases and inflammation research: a bibliometric analysis.

Wang H, Chen Y, Gou Y, Yang D, Xiong L Front Med (Lausanne). 2024; 11:1388665.

PMID: 39371339 PMC: 11449749. DOI: 10.3389/fmed.2024.1388665.


Current Understanding of Cardiovascular Calcification in Patients with Chronic Kidney Disease.

Chen S, Tang R, Liu B Int J Mol Sci. 2024; 25(18).

PMID: 39337709 PMC: 11432307. DOI: 10.3390/ijms251810225.


Key regulators of vascular calcification in chronic kidney disease: Hyperphosphatemia, BMP2, and RUNX2.

Liang X, Li Y, Wang P, Liu H PeerJ. 2024; 12:e18063.

PMID: 39308809 PMC: 11416758. DOI: 10.7717/peerj.18063.


Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in CKD.

Miyazaki-Anzai S, Masuda M, Keenan A, Shiozaki Y, Miranda J, Miyazaki M JCI Insight. 2024; 9(7).

PMID: 38470493 PMC: 11128211. DOI: 10.1172/jci.insight.174977.


References
1.
Zhang Y, Lei C, Hu Y, Xia T, Li M, Zhong B . Krüppel-like factor 6 is a co-activator of NF-κB that mediates p65-dependent transcription of selected downstream genes. J Biol Chem. 2014; 289(18):12876-85. PMC: 4007475. DOI: 10.1074/jbc.M113.535831. View

2.
Zhang J, Zhong W, Cui T, Yang M, Hu X, Xu K . Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol. 2006; 26(3):e23-4. PMC: 4207359. DOI: 10.1161/01.ATV.0000202661.61837.93. View

3.
Zhao G, Xu M, Zhao M, Dai X, Kong W, Wilson G . Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 2012; 82(1):34-44. PMC: 3376207. DOI: 10.1038/ki.2012.40. View

4.
Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y . Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013; 37(4):346-58. DOI: 10.1159/000348805. View

5.
Descamps-Latscha B, Herbelin A, Nguyen A, Roux-Lombard P, Zingraff J, Moynot A . Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995; 154(2):882-92. View